T Louie

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. ncbi How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?
    Thomas J Louie
    Infectious Diseases Division, Department of Medicine, University of Calgary, Alta
    CMAJ 173:1049-50. 2005
  2. ncbi Clostridium difficile infection in hospitals: risk factors and responses
    Thomas J Louie
    Department of Medicine, University of Calgary
    CMAJ 171:45-6. 2004
  3. ncbi Understanding influenza vaccination attitudes at a Canadian cancer center
    Manuel W Mah
    Infection Prevention and Control Program, Calgary Health Region, The University of Calgary, Canada
    Am J Infect Control 33:243-50. 2005
  4. ncbi Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea
    Thomas J Louie
    University of Calgary, Calgary, Alberta, Canada
    Clin Infect Dis 43:411-20. 2006
  5. ncbi Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)
    Aric J Storck
    Department of Emergency Medicine, Calgary Health Region, Calgary, Alberta, Canada
    BMC Infect Dis 6:148. 2006
  6. ncbi Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection
    T Louie
    University of Calgary, Calgary, Alberta, Canada
    Antimicrob Agents Chemother 53:223-8. 2009
  7. ncbi Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease
    B Guo
    Institute of Health Economics, Edmonton, Alberta, Canada
    Aliment Pharmacol Ther 35:865-75. 2012
  8. ncbi Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada
    Duncan R MacCannell
    Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
    J Clin Microbiol 44:2147-52. 2006
  9. ncbi Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options
    Thomas J Louie
    Clin Infect Dis 42:765-7. 2006
  10. ncbi Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains
    Kevin B Laupland
    Department of Medicine, University of Calgary, Centre for Anti-microbial Resistance, and Calgary Health Region, Calgary, Alberta, Canada
    J Infect Dis 192:1606-12. 2005

Collaborators

Detail Information

Publications12

  1. ncbi How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?
    Thomas J Louie
    Infectious Diseases Division, Department of Medicine, University of Calgary, Alta
    CMAJ 173:1049-50. 2005
  2. ncbi Clostridium difficile infection in hospitals: risk factors and responses
    Thomas J Louie
    Department of Medicine, University of Calgary
    CMAJ 171:45-6. 2004
  3. ncbi Understanding influenza vaccination attitudes at a Canadian cancer center
    Manuel W Mah
    Infection Prevention and Control Program, Calgary Health Region, The University of Calgary, Canada
    Am J Infect Control 33:243-50. 2005
    ..Understanding health care worker perceptions and needs is essential for improving rates of vaccination...
  4. ncbi Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea
    Thomas J Louie
    University of Calgary, Calgary, Alberta, Canada
    Clin Infect Dis 43:411-20. 2006
    ..difficile-associated diarrhea, and selection for nosocomial pathogens. Tolevamer, a soluble, high-molecular weight, anionic polymer that binds C. difficile toxins A and B is a unique nonantibiotic treatment option...
  5. ncbi Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)
    Aric J Storck
    Department of Emergency Medicine, Calgary Health Region, Calgary, Alberta, Canada
    BMC Infect Dis 6:148. 2006
    ..The objective of this study was to develop a health-related quality of life questionnaire (HRQL) for patients with extremity soft tissue infections (ESTI) for future use in clinical trials...
  6. ncbi Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection
    T Louie
    University of Calgary, Calgary, Alberta, Canada
    Antimicrob Agents Chemother 53:223-8. 2009
    ....
  7. ncbi Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease
    B Guo
    Institute of Health Economics, Edmonton, Alberta, Canada
    Aliment Pharmacol Ther 35:865-75. 2012
    ..Management of recurrent Clostridium difficile-associated disease (CDAD), particularly in elderly patients, remains clinically challenging. Faecal transplantation (FT) may restore normal microbiota and break the cycle of recurrent CDAD...
  8. ncbi Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada
    Duncan R MacCannell
    Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
    J Clin Microbiol 44:2147-52. 2006
    ..PCR ribotype 027 strains appear to be widely distributed, to predate the Montreal outbreak, and to have measurable community presence in Western Canada...
  9. ncbi Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options
    Thomas J Louie
    Clin Infect Dis 42:765-7. 2006
  10. ncbi Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains
    Kevin B Laupland
    Department of Medicine, University of Calgary, Centre for Anti-microbial Resistance, and Calgary Health Region, Calgary, Alberta, Canada
    J Infect Dis 192:1606-12. 2005
    ..aeruginosa strains were associated with a higher case-fatality rate and invasive disease. Our study highlights the potential importance of molecular laboratory techniques in infection control and patient care...
  11. ncbi Population-based assessment of intensive care unit-acquired bloodstream infections in adults: Incidence, risk factors, and associated mortality rate
    Kevin B Laupland
    Division of Critical Care Medicine, University of Calgary, Calgary Health Region, Alberta, Canada
    Crit Care Med 30:2462-7. 2002
    ..In our region, multiple antibiotic-resistant organisms are uncommon causes of bloodstream infections, suggesting that it may be safe to use narrower spectrum empirical treatment regimens than current guidelines recommend...
  12. ncbi Incidence and risk factors for acquiring nosocomial urinary tract infection in the critically ill
    Kevin B Laupland
    Division of Critical Care Medicine, University of Calgary, Calgary Health Region, Canada
    J Crit Care 17:50-7. 2002
    ..CONCLUSIONS: Nosocomial UTIs develop commonly in the critically ill and women and those with an extended ICU stay are at increased risk. Although ICU-acquired UTIs are markers of morbidity, they do not significantly increase mortality...